Optic Neuritis Post Immune Checkpoint Inhibitor Therapy

May Ameri; Nagham Al-Zubidi; Andrew Whyte

doi:10.1007/978-3-031-83533-9_43

Optic Neuritis Post Immune Checkpoint Inhibitor Therapy

May Ameri
, Nagham Al-Zubidi
, Andrew Whyte

Head & Neck Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This was a patient with melanoma that developed optic neuritis 11 days after second cycle of pembrolizumab treatment. Patient improved with intravenous steroid and withholding pembrolizumab, although vision did not return to baseline post treatment, patient’s visual field and optic disc edema improved. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing different cancer treatment and was discharged to follow-up with local ophthalmologist.

Original language	English (US)
Title of host publication	Challenging Cases in Immunotherapy Related Organ Toxicities
Publisher	Springer Science+Business Media
Pages	337-344
Number of pages	8
ISBN (Electronic)	9783031835339
ISBN (Print)	9783031835322
DOIs	https://doi.org/10.1007/978-3-031-83533-9_43
State	Published - Jan 1 2025

Keywords

Immune-checkpoint inhibitors
Ocular immune related adverse events
Optic neuritis
Optic neuropathy
Pembrolizumab

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-83533-9_43

Cite this

@inbook{def7a9871ab54671aeaabc11ede71954,

title = "Optic Neuritis Post Immune Checkpoint Inhibitor Therapy",

abstract = "This was a patient with melanoma that developed optic neuritis 11 days after second cycle of pembrolizumab treatment. Patient improved with intravenous steroid and withholding pembrolizumab, although vision did not return to baseline post treatment, patient{\textquoteright}s visual field and optic disc edema improved. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing different cancer treatment and was discharged to follow-up with local ophthalmologist.",

keywords = "Immune-checkpoint inhibitors, Ocular immune related adverse events, Optic neuritis, Optic neuropathy, Pembrolizumab",

author = "May Ameri and Nagham Al-Zubidi and Andrew Whyte",

note = "Publisher Copyright: {\textcopyright} 2025 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.",

year = "2025",

month = jan,

day = "1",

doi = "10.1007/978-3-031-83533-9\_43",

language = "English (US)",

isbn = "9783031835322",

pages = "337--344",

booktitle = "Challenging Cases in Immunotherapy Related Organ Toxicities",

publisher = "Springer Science+Business Media",

}

TY - CHAP

T1 - Optic Neuritis Post Immune Checkpoint Inhibitor Therapy

AU - Ameri, May

AU - Al-Zubidi, Nagham

AU - Whyte, Andrew

PY - 2025/1/1

Y1 - 2025/1/1

N2 - This was a patient with melanoma that developed optic neuritis 11 days after second cycle of pembrolizumab treatment. Patient improved with intravenous steroid and withholding pembrolizumab, although vision did not return to baseline post treatment, patient’s visual field and optic disc edema improved. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing different cancer treatment and was discharged to follow-up with local ophthalmologist.

AB - This was a patient with melanoma that developed optic neuritis 11 days after second cycle of pembrolizumab treatment. Patient improved with intravenous steroid and withholding pembrolizumab, although vision did not return to baseline post treatment, patient’s visual field and optic disc edema improved. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing different cancer treatment and was discharged to follow-up with local ophthalmologist.

KW - Immune-checkpoint inhibitors

KW - Ocular immune related adverse events

KW - Optic neuritis

KW - Optic neuropathy

KW - Pembrolizumab

UR - https://www.scopus.com/pages/publications/105022231509

UR - https://www.scopus.com/pages/publications/105022231509#tab=citedBy

U2 - 10.1007/978-3-031-83533-9_43

DO - 10.1007/978-3-031-83533-9_43

M3 - Chapter

AN - SCOPUS:105022231509

SN - 9783031835322

SP - 337

EP - 344

BT - Challenging Cases in Immunotherapy Related Organ Toxicities

PB - Springer Science+Business Media

ER -

Optic Neuritis Post Immune Checkpoint Inhibitor Therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this